Takeda Pharmaceutical has entered a multi-year partnership worth more than $1.7 billion with privately held Iambic to leverage artificial intelligence in developing small-molecule drugs for cancer and gastrointestinal diseases. The agreement includes upfront payments and potential milestone payments exceeding $1.7 billion, plus royalties on future sales. This deal represents Takeda's latest push to integrate AI across its research operations.

Iambic's NeuralPLexer model, which predicts how drug molecules bind to proteins, will be central to the collaboration. The Japanese pharmaceutical giant has been steadily expanding its AI capabilities, having previously partnered with Nabla Bio last year for protein-based drug development. Drug developers increasingly view AI as a tool to accelerate discovery timelines and reduce costs, with some experts predicting development timelines could be halved in coming years.

Traditional drug discovery typically requires around six years before compounds reach clinical trials, but Iambic claims its AI-driven approach combined with automated laboratories can compress this timeline to under two years. Takeda's Chief Scientific Officer Christopher Arendt emphasized that while speed matters, molecular quality remains equally critical. The partnership underscores the pharmaceutical industry's growing confidence in AI's potential to transform drug development, moving beyond traditional trial-and-error methods to more targeted, efficient discovery processes.